Evaluation of medication safety in the discharge medication of 509 surgical inpatients using electronic prescription support software and an extended operational interaction classification

**Thomas Frölich · Olesya Zorina · Andrea O. Fontana ·
Gerd A. Kullak-Ublick · Andreas Vollenweider ·
Stefan Russmann**

Abstract

Purpose Our aim was to study drug interactions and dose adjustments in patients with renal impairment in the discharge medication of surgical inpatients and to evaluate the strengths and limitations of clinical decision support software (CDSS) for this task.

Methods This was a cross-sectional study involving 509 surgical patients of a primary care hospital. We developed a customized interface for the CDSS MediQ, which we used for automated retrospective identification of drug interactions in the patients' discharge medication. The clinical relevance of the interactions was evaluated based on the Zurich Interaction System (ZHIAS) that incorporates the operational classification of drug interactions (ORCA). Prescriptions were further analyzed for recommended dose adjustments in patients with a glomerular filtration rate <60 ml/min.

Results For the total of 2,729 prescriptions written for the 509 patients enrolled in the study, MediQ generated 2,558 interaction alerts and 1,849 comments. Among these were ten "high danger" and 551 "average danger" alerts that we reclassified according to ORCA criteria. This reclassification resulted in ten contraindicated combinations, 77 provisionally contraindicated combinations, and 310 with a conditional and 164 with a minimal risk of adverse outcomes. The ZHIAS classification also provides categorical information on expected adverse outcomes and management recommendations, which are presented in detail. We identified 56 prescriptions without a recommended dose adjustment for impaired renal function.

Conclusions CDSS identified a large number of drug interactions in surgical discharge medication, but according to ZHIAS criteria only a minor fraction of these appeared to involve a substantial risk to the patient. CDSS should therefore aim at reducing over-alerting and improve usability in order to become more efficacious in terms of the prevention of adverse drug events in clinical practice.

Keywords Clinical decision support software · Dose adjustment · Drug interactions · Surgery

T. Frölich · O. Zorina · A. O. Fontana · G. A. Kullak-Ublick ·
S. Russmann (✉)
Department of Clinical Pharmacology and Toxicology,
University Hospital Zurich,
Rämistrasse 100,
8091 Zurich, Switzerland
e-mail: stefan.russmann@usz.ch

T. Frölich · A. Vollenweider
Department of Surgery, Regional Hospital Männedorf,
Männedorf, Switzerland

G. A. Kullak-Ublick · S. Russmann
Zurich Center for Integrative Human Physiology (ZIHP),
University of Zurich,
Zurich, Switzerland

Introduction

Drug interactions and resulting adverse drug events (ADE) are important pharmacotherapeutic challenges. They cause considerable morbidity, mortality, and costs and have been estimated to be responsible for 1% of all hospital admissions [1–5]. Computerized physician order entry (CPOE) combined with clinical decision support software (CDSS) has been proposed as a valuable tool to

prevent critical interactions and also to guide dose adjustment in patients with impaired renal function. Several studies have obtained encouraging results using this tool [6, 7], with one study demonstrating a significant 81% reduction in medication errors after the introduction of CPOE with CDSS [8]. However, several more recent studies concluded that commonly used CDSS suffer from "over-alerting" and that the resulting "alert-fatigue" among physicians is an important reason why they often fail to effectively improve medication safety in clinical practice [9–12]. Furthermore, the frequency of specific critical medication problems varies between different specialties and settings. It is our belief that the first aim of new approaches should be a highly efficient analysis of local safety issues, as the findings from such analyses may subsequently support the development of targeted local measures in order to improve pharmacotherapy. In particular, we have found that more data is needed on surgical inpatients in order to be able to evaluate medication safety for this population.

The study reported here therefore had two major aims. The first was to describe and quantify medication safety with regard to drug interactions and renal dose adjustments in patients discharged from surgical care in a regional Swiss hospital using a new highly efficient CDSS interface for retrospective interaction analysis. The second was to improve the specificity of CDSS in identifying clinically relevant drug interactions and providing related practical prescribing information.

Material and methods

Study design

This was a cross-sectional study involving all surgical patients discharged between 1 January and 31 October 2009 from a primary care regional hospital, including patients from general surgery, orthopedics, urology, otorhinolaryngology, and reconstructive surgery. The only exclusion criterion was admission to the hospital for fewer than 4 nights; patients with a shorter stay were excluded in order to assure that the pharmacotherapy was actively managed and well documented by the treating surgeons. The regional ethics committee approved the study protocol, including access to the hospital's clinical information system for the purposes of the study.

Pharmacotherapy at discharge, demographics, medical diagnoses, and laboratory test results were retrospectively retrieved for each patient from their original medical records and the hospital's clinical information system, and data on all patients were stored in an anonymized master file. The latest available value for serum creatinine before discharge was used to estimate renal function according to the Modification of Diet in Renal Disease (MDRD) Study–glomerular filtration rate (GFR) formula [13]. All drugs were then matched to their corresponding Anatomical Therapeutic Chemical (ATC) Classification System codes, and single drugs that contained several active ingredients were split into their component substances and treated as separate prescriptions for all further analyses.

The data thus obtained were analyzed for the following outcomes of interest: (1) frequency and severity grading of drug interactions according to the commercially available CDSS MediQ; (2) extended classification and evaluation of the clinical relevance of interactions identified by MediQ according to the Zurich Interaction System (ZHIAS); (3) compliance with recommended dose adjustments in patients with an estimated GFR <60 ml/min based on MediQ alerts, Aronoff's *Drug prescribing in renal failure* [14], and the manufacturers' national prescribing information (Arzneimittel-Kompendium der Schweiz). Figure 1 shows an overview of the study procedures and global results.

MediQ and development of a customized interface for mass analysis

MediQ is a commercial CDSS for use as an Internet application (www.mediq.ch). The user manually enters concomitantly prescribed drugs for individual patients, and MediQ then identifies interactions and generates the following output. The first information generated is a four-level categorical severity grading that MediQ describes as: 3 = "high" or "strong interaction"; 2 = "average" or "clinically relevant interaction"; 1="low" or an interaction that is "relevant in exceptional cases"; 0="no interaction" or additional comments. This information is also presented in a matrix overview. Second, detailed free text information for each interaction. Third, additional tables are generated that present pharmacokinetic effects on metabolizing enzymes and drug transporters as well as pharmacodynamic effects on the central nervous system for individual substances.

Because the manual entry of prescriptions for each patient would not be efficient for our purposes we developed, in collaboration with MediQ, a customized data interface for mass analysis. This allowed us to upload one structured text file over the Internet that contained an anonymous study number and the corresponding ATC codes of concomitantly prescribed drugs for each patient. Exactly the same analyses as for the usual Internet application were then executed on the MediQ server. The results could subsequently be downloaded over the Internet and imported into statistical software for further analyses. Because MediQ's knowledge database is continuously updated, it should be noted here that the interaction

Fig. 1 Overview of study procedures and global results. *ZHIAS* Zurich Interaction System, *GFR* glomerular filtration rate

analyses presented in this study were all executed in July 2010.

ZHIAS classification

ZHIAS is an extended drug interaction classification system that was developed at our department while carrying out this and other related studies. It features four major dimensions plus free text fields. The first dimension uses the well-established and documented five-level grading according to the OpeRational ClassificAtion of drug interactions (ORCA) criteria [15]. Briefly, ORCA's five operational levels are defined as follows:

> Grade 1="contraindicated combination". The risk of such a combination always outweighs the benefit.

Grade 2="provisionally contraindicated". The combination should be avoided unless an interaction is desired or no alternative is available; monitoring may be necessary.
Grade 3="conditional risk". Monitoring or alternatives should be considered.
Grade 4="minimal risk". No special action is needed.
Grade 5="no interaction".

ZHIAS's other three major dimensions use dichotomous variables that relate to patient management, interaction mechanisms, and adverse effects with an increased risk resulting from an interaction (see Table 4). For the current study an expert panel consisting of a surgeon (TF), two pharmacists (OZ and AF), and a clinical pharmacologist (SR) discussed the ZHIAS classifications of identified

interactions until common agreement was achieved. For our assessments we referred to original and secondary literature, including—but not limited to—Hansten and Horn's *Drug interactions: analysis and management* [16], and *Stockley's drug interactions* [17].

Data analysis

Data analysis was descriptive with presentation of results in text, tables, and figures, and the calculation of medians, means, and proportions as appropriate. Data management and analyses were performed with STATA ver. 11.1 for MacOS X (STATA Corp, College Station, TX) and SPSS ver. 19 for Windows (SPSS, Chicago, IL).

Results

Selection and characteristics of the study population

Demographic data of 552 consecutive surgical patients hospitalized for at least 4 nights at the Department of Surgery were retrieved from the hospital's electronic information system. Thereafter, the patients' discharge medication was abstracted from their original medical records, including discharge letters. Forty-three patients were subsequently excluded because they had only one or no prescription. The characteristics of all remaining 509 patients enrolled in the study are presented in Table 1. The mean age of the patients was 60.4 (median 70.7, range 8–99) years. The median number of concomitantly prescribed substances per patient was five (range 2–17). Table 1 also presents polypharmacy distribution over three broad categories. The frequency of prescriptions over drug classes is shown in Table 2. Nonsteroidal anti-inflammatory drugs (NSAIDs), with paracetamol (acetaminophen) and metamizol (dipyrone), was the most commonly prescribed drug class, followed by antithrombotics and cardiovascular agents.

Identification and evaluation of drug interactions

Automated analysis using MediQ generated 2,558 interaction alerts and 1,849 additional comments (Fig. 1). As expected, the number of interaction alerts per patient markedly increased with a higher number of concomitantly prescribed substances (Fig. 2).

Table 3 presents the results of the automated drug interaction analysis using MediQ along with our subsequent reclassification of MediQ "high" and "average" danger alerts according to ORCA criteria. Of ten combinations considered by MediQ as involving a "high danger" interaction, none was classified as contraindicated, and

Table 1 Characteristics of the study patients ($n=509$)

Characteristics	n	Percentage of patient cohort
Sex		
Female	280	55.0
Male	229	45.0
Age category (years)		
<25	20	3.9
25–44	46	9.0
45–64	138	27.1
65–84	243	47.7
≥85	62	12.2
Primary admission diagnosis[a]		
Trauma	209	41.1
Visceral surgery	121	23.8
Orthopedics	101	19.8
Urology	22	4.3
Other	56	11.0
Admission		
Elective	196	38.5
Emergency	313	61.5
Duration of hospitalization (nights)		
4–6	173	34.0
7-10	152	29.9
11–30	172	33.8
>30	12	2.4
Renal function (MDRD-GFR, ml/min/1.73 m^2)[b]		
≥60	408	80.2
30–59	61	12.0
<30 or dialysis	4	0.8
Unknown	36	7.1
Number of concomitant drugs (polypharmacy)		
2–4	250	49.1
5–8	173	34.0
≥9	86	16.9

MDRD-GFR, Modification of Diet in Renal Disease (MDRD) Study–glomerular filtration rate

[a] Only one primary diagnosis per patient

[b] Last measurement before discharge

only one was classified as provisionally contraindicated according to ORCA criteria. Of the 551 prescriptions considered by MediQ as involving an "average danger", ten were classified as "contraindicated" and 76 as "provisionally contraindicated". The full evaluation of all MediQ high and average danger interaction alerts showing all ZHIAS dimensions is presented in Table 4. Based on our evaluation of the management of interactions according to ZHIAS, we concluded that 28.6% of provisionally contraindicated combinations and 21.9% of combinations with a conditional risk were most likely actually desired combinations with an acceptable risk–benefit ratio under the

Table 2 Discharge medication of the study population

Drugs	Prescriptions		Patients with prescriptions	
	n	%	*n*	%
Total	2,729	100	509	100
NSAIDs including paracetamol and metamizol[a]	712	26.1	446	87.6
Antithrombotics[a]	447	16.4	316	62.1
RAA system inhibitors and diuretics	280	10.3	178	35.0
Other cardiovascular agents	249	9.1	168	33.0
Gastrointestinal agents	228	8.4	204	40.1
Anti-infective agents	143	5.2	109	21.4
Dietary supplements	123	4.5	76	14.9
Opioids	82	3.0	74	14.5
Antidepressants	79	2.9	63	12.4
Antidiabetic agents	78	2.9	51	10.0
Other nervous system agents	53	1.9	44	8.6
Anxiolytics, sedatives and hypnotics	49	1.8	43	8.4
Antipsychotics	47	1.7	40	7.9
Hormones	45	1.6	41	8.1
Respiratory tract agents	37	1.4	24	4.7
Anticonvulsants	28	1.0	24	4.7
Antineoplastic and immunological agents	7	0.3	7	1.4
Other	42	1.5	39	7.7

NSAID, Nonsteroidal anti-inflammatory drugs

RAA, Renin–angiotensin–aldosterone

[a] Low-dose acetylsalicylic acid is included among antithrombotics but not under NSAIDs

condition that patients are appropriately monitored. Nevertheless, at the same time, in more than 70% of the combinations there may exist alternative treatments with a possibly more favorable risk–benefit ratio. In terms of mechanisms, pharmacodynamic interactions were most

Fig. 2 Correlation between polypharmacy and identification of interactions by different danger categories for interactions according to the MediQ

frequent over all ORCA classes, and increased drug effects, particularly increased risk of bleeding, were the most frequently encountered potential adverse consequences resulting from interactions.

Specific interacting combinations with the highest danger rating according to MediQ or ORCA are presented in Table 5. MediQ classified six specific combinations as "high danger". In these cases, ORCA criteria emphasize that even if the potential adverse effect may be severe, it is possible to manage all of these interactions with appropriate monitoring, such as for hyperkalemia or QTc prolongations, followed by dose adjustment or stop of therapy if necessary. In contrast, those combinations with the highest ORCA rating may not necessarily be driven by a very high risk or severity of an adverse event: in eight out of ten cases the combined drugs have the same mechanism of action, and for two, the weak evidence supporting ginkgo's efficacy led to our assessment of a generally unfavorable risk–benefit ratio. Table 6 presents all specific drug interactions classified by ZHIAS as ORCA 2 ("provisionally contraindicated") and the ten most frequent specific drug interactions classified as ORCA 3 ("conditional risk"). This overview also shows that MediQ identified a large number of interactions that may increase the risk of bleeding in the studied surgical population and assigns them an "average" risk. The multidimensional ZHIAS evaluation additionally distinguished a more relevant bleeding risk if NSAIDs are combined with the oral anticoagulant phenprocoumon from a lower risk when combined with low-dose heparins and

Table 3 Identification and grading of interactions by MediQ and subsequent reclassification based on ORCA criteria for MediQ level 2 and 3 alerts as part of the ZHIAS classification

Drug interaction classifications	Frequency of distinct combinations in the 509 patients		Frequency of combined prescriptions in the 509 patients	
	n	%	n	%
MediQ level 3 ("high")	5	100	10	100
ORCA level 1 ("contraindicated")	0	0	0	0
ORCA level 2 ("provisionally contraindicated")	1	20.0	1	10.0
ORCA level 3 ("conditional risk")	3	60.0	8	80.0
ORCA level 4 ("minimal risk")	1	20.0	1	10.0
MediQ level 2 ("average")	149	100	551	100
ORCA level 1 ("contraindicated")	9	6.0	10	1.8
ORCA level 2 ("provisionally contraindicated")	10	6.7	76	13.8
ORCA level 3 ("conditional risk")	94	63.1	302	54.8
ORCA level 4 ("minimal risk")	36	24.2	163	29.6
MediQ level 1 ("low")	529	100	1,997	100
MediQ level 0 ("no interaction")	499	100	1,849	100

ORCA, OpeRational ClassificAtion of drug interactions; ZHIAS, Zurich Interaction System

recognized that low-dose aspirin combined with phenprocoumon may carry a substantial risk but that this is often a desired combination.

Dose adjustment in patients with impaired renal function

Creatinine measurements and corresponding MDRD–GFR estimations were available for 473 (92.9%) of the 509 patients; of these, 65 patients (12.8%) had renal impairment with a GFR <60 ml/min. Those patients received a total of 448 prescriptions for 61 distinct substances, which we analyzed for compliance with recommended dose adjustments. According to the MediQ, 26 substances accounting for 247 prescriptions in 58 patients require dose adjustment in the case of impaired renal function, and we identified a failure to comply with recommended dose adjustment in 56 prescriptions for 44 patients. These are presented in Table 7, along with our assessment of 14 prescriptions having a major and 42 a minor risk of resulting in a related adverse event.

Discussion

In this study, we used a customized interface with the CDSS MediQ to retrospectively identify drug interactions and substances that require dose adjustment for renal impairment in the discharge medication of surgical inpatients. MediQ was able to detect a very large number of (potential) drug interactions and therefore readily demonstrates the typical major strength as well as limitation of a CDSS.

Although this study was not designed to evaluate the sensitivity of MediQ to detect drug interactions, our results and the fact that its database contains about 2,000 substances and 20,000 detailed comments on related drug interactions suggest that MediQ is indeed a highly sensitive tool for the detection of interactions. On the other hand, our further evaluation based on ORCA and extended ZHIAS criteria led us to the conclusion that only a minor fraction of alerts generated by MediQ is associated with a substantial risk that would require medication changes. This is of particular concern as such a low specificity with regard to clinically relevant information can be expected to compromise a physician's compliance to use such a system in daily practice [9–12]. In contrast, previous studies have shown that focused information that has been pre-selected by clinical pharmacologists and pharmacists and then clearly communicated to treating physicians does have a long-lasting effect on reducing the number of prescriptions for interacting drug combinations [5]. Our own experience from daily safety ward rounds at a university hospital are also in agreement with this finding, but in most clinical settings such resource intensive services are not routinely available. Furthermore, one-dimensional, three-level "traffic light" grading systems, such as one used by MediQ, do not necessarily correlate with the clinical relevance of the alerts [15, 18]. Therefore, filtering those alerts with high or average danger ratings does not reliably solve the issue of over-alerting. ORCA and ZHIAS consequently attempt a different approach, i.e. to focus on clinical management and to record additional information in a categorical format. Although MediQ also contains additional information of

Table 4 ZHIAS reclassification by ORCA categories of all 561[a] interactions classified by MediQ as high or average danger and their corresponding frequencies in the study population

ZHIAS classification	Frequencies in 509 patients, stratified over ORCA classes					
	ORCA 1 (contraindicated/risk outweighs benefit)		ORCA 2 (provisionally contraindicated)		ORCA 3 (conditional risk)	
	n	%	n	%	n	%
Total combinations	10	100	77	100	310	100
Management						
Desired	0	0	22	28.6	68	21.9
Consider alternative	10	100	55	71.4	247	79.7
Monitoring	0	0	77	100	263	84.8
Mechanism[b]						
Pharmacokinetic	0	0	6	7.8	56	18.1
Pharnacodynamic	10	100	74	96.1	275	88.7
Adverse events with increased risk resulting from interactions[c]						
Increased drug effect	8	80.0	75	97.4	216	69.7
Decreased drug effect	1	10.0	1	1.3	46	14.8
Sedation (CNS)	4	40.0	5	6.5	17	5.5
Serotonin syndrome	1	10.0	1	1.3	21	6.8
Extrapyramidal symptoms	0	0	1	1.3	1	0.3
Seizures	2	20.0	1	1.3	17	5.5
CNS effects other	3	30.0	2	2.6	6	1.9
Nephrotoxicity	3	30.0	1	1.3	37	11.9
Hepatotoxicity	0	0	0	0	4	1.3
QTc prolongation	0	0	2	2.6	17	5.5
Cardiac arrhythmias	0	0	3	3.9	27	8.7
Thrombosis	0	0	0	0	6	1.9
Bleeding	4	40.0	70	90.9	171	55.2
Blood pressure up	0	0	0	0	34	11.0
Blood pressure down	1	10.0	3	3.9	22	7.1
Cardiovascular effects other	0	0	0	0	11	3.5
Hyperkalemia	1	10.0	0	0	39	12.6
Hypokalemia	0	0	0	0	9	2.9
Hyponatremia	0	0	1	1.3	5	1.6
Metabolic/endocrine effects	0	0	1	1.3	1	0.3
Gastrointestinal toxicity	2	20.0	1	1.3	8	2.6
Blood glucose up	0	0	1	1.3	2	0.6
Blood glucose down	0	0	0	0	2	0.6
Muscular toxicity	0	0	1	1.3	7	2.3
Allergy	0	0	0	0	4	1.3
Other	0	0	0	0	8	2.6

CNS, Central nervous system; QTc, QT interval corrected for heart rate

[a] Another 164 interactions classified by MediQ as high or average danger were reclassified into ORCA 4=minimal risk (see Table 3) and are not shown in detail in this table

[b] Pharmacokinetic and Pharmacodynamic mechanisms can be involved concomitantly, and the combined total may therefore exceed 100%

[c] Several adverse events may result from one combination, and the combined total may therefore exceed 100%

high quality for clinical management in its free text comments, that information is easily overseen unless one has the time to read them all. In contrast, based on its underlying categorical format, ZHIAS can readily display the same information in an accordingly designed CDSS and therefore provides the basis to present it at first glance to

Table 5 Presentation of all specific interactions with the highest severity rating according to MediQ ("high danger")and/or ZHIAS (ORCA 1, "contraindicated/risk always outweighs benefit")

Drug combination	Frequency in 509 patients		MediQ danger rating	ZHIAS classification		
	n	%		ORCA[a]	Management[b]	Adverse event with increased risk
Lisinopril–spironolactone	5	1.0	High	3	A/M	Hyperkalemia
Atorvastatin–amiodarone	2	0.4	High	3	A/M	Muscle toxicity
Paroxetine–metoprolol	1	0.2	High	2	A/M	Hypotension, bradycardia
Salmeterol–amiodarone	1	0.2	High	3	M	QTc, arrhythmias
Melitracen–amiodarone	1	0.2	High	4	M	QTc, arrhythmias
Tramadol–oxycodone	2	0.4	Average	1	A	Sedation, seizures
Tramadol–buprenorphine	1	0.2	Average	1	A	Sedation, seizures
Tramadol–codeine	1	0.2	Average	1	A	Sedation, seizures
Tramadol–fentanyl	1	0.2	Average	1	A	Sedation, seizures, serotonin syndrome
Lisinopril–irbesartan	1	0.2	Average	1	A	Hyperkalemia, renal deterioration
Ginkgo biloba–phenprocoumon	1	0.2	Average	1	A	Bleeding
Ginkgo biloba–clopidogrel	1	0.2	Average	1	A	Bleeding
Mefenamic acid–diclofenac	1	0.2	Average	1	A	GI bleeding
Mefenamic acid–ibuprofen	1	0.2	Average	1	A	GI bleeding

GI, Gastrointestinal

[a] ORCA notation: 1 = contraindicated, 2 = provisionally contraindicated, 3 = conditional risk, 4 = minimal risk

[b] D, Desired interaction; A, consider an available alternative; M, special monitoring recommended

the treating physician. For example, for the interaction between lisinopril and spironolactone (see Table 5), a CDSS using ZHIAS data is able to immediately direct the prescriber's attention to the current serum potassium value through one simple activated icon or even directly trigger retrieval of the latest measurement from the hospital's electronic patient information system. If potassium is indeed elevated, a warning can be displayed with a high level of importance, whereas no further action besides monitoring (which can also be triggered through a ZHIAS-based system) would be required in the case of a normal value. Furthermore, expert analysis of local results could help to put more emphasis on interactions that have frequently led to problems in the past in a specific setting or are otherwise of special interest. For example, recent data support the view that not only "typical" NSAIDs but also metamizol can increase the risk of bleeding through inhibition of prostaglandin synthesis, which may be of special interest in a setting where this drug is frequently used as an analgesic after surgery [19, 20]. Finally, our finding that doses were apparently not adjusted for impaired renal function in 9% of all patients and in 68% of patients with a GFR <60 ml/min emphasizes that automated warnings for dose adjustment should also be part of integrated CPOE and CDSS.

Overall our results suggest that both the integration of CDSS into the daily clinical prescription workflow as well as their design and content require major changes in order to effectively improve medication safety in real-life settings. First, clinically important interaction alerts must be automatically displayed at the time of prescription. Second, in order to avoid over-alerting by automated CDSS a paradigm shift may be necessary, away from a CDSS with maximum sensitivity and towards a CDSS with the best possible specificity for clinically relevant alerts. Third, we must therefore increase our efforts to define clinically relevant interactions and consider risk factors in order to implement that information into improved CDSS. The implementation of ZHIAS into a CDSS is one possible solution that we explored in our study. Additional studies will now be necessary to show whether accordingly modified CDSS are able to actually modify prescribing behavior and reduce adverse drug events. However, we also conclude that any CDSS can only change prescribing behavior if its introduction is well coordinated and accompanied by intense personal communication with local prescribers, further local customization, and subsequent constant reevaluations. This process calls for a bridging function between theoretical pharmacological knowledge and clinical expertise, which can be a challenging new task for clinical pharmacologists. In our case, we discussed critical interactions and doses with the prescribing surgeons. Our next aim is to introduce automated alerts at the time of prescriptions that are locally co-developed and supported by the Department of Surgery, followed by a systematic outcome evaluation.

Table 6 Presentation of all specific drug interactions classified by ZHIAS as ORCA 2 ("provisionally contraindicated"), and the ten most frequent specific drug interactions classified as ORCA 3 ("conditional risk") in the 509 patients

Drug combination	Frequency in 509 patients		MediQ danger rating	ORCA[a]	Management[b]	Adverse event with increased risk
	n	%				
All combinations classified as "provisionally contraindicated" by ZHIAS						
Mefenamic acid–phenprocoumon	48	9.4	Average	2	A / M	Bleeding
Low dose acetylsalicylic acid–phenprocoumon	20	3.9	Average	2	D / M	Bleeding
Any two benzodiazepines	2	0.4	Average	2	D / M	Sedation
Metoprolol–paroxetine	1	0.2	High	2	A / M	Bradycardia, hypotension
Amiodarone–nebivolol	1	0.2	Average	2	A / M	Bradycardia, hypotension
Fluoxetine–citalopram	1	0.2	Average	2	A / M	Hyponatremia, serotonin syndrome
Ginkgo biloba–mefenamic acid	1	0.2	Average	2	A / M	Bleeding
Lithium–mefenamic acid	1	0.2	Average	2	A / M	Lithium intoxication
Quetiapine–primidone	1	0.2	Average	2	A / M	Sedation, loss of quetiapine efficacy
Valproic acid–phenobarbital	1	0.2	Average	2	A / M	Sedation, other CNS
Ten most frequent combinations classified as "conditional risk" by ZHIAS						
Mefenamic acid–dalteparin	69	13.6	Average	3	A / M	Bleeding
Low dose acetylsalicylic acid–dalteparin	31	6.1	Average	3	D / M	Bleeding
Metamizol–phenprocoumon	28	5.5	Average	3	A / M	Bleeding
Mefenamic acid–metamizol	12	2.4	Average	3	D / M	Bleeding
Mefenamic acid–lisinopril	10	2.0	Average	3	A / M	Hypertension, nephrotoxicity
Diclofenac–dalteparin	8	1.6	Average	3	A / M	Bleeding
Tramadol–citalopram/escitalopram	6	1.2	Average	3	A / M	Serotonin syndrome
Allopurinol–amoxicillin	4	0.8	Average	3	A / M	Exanthema, skin rashes
Allopurinol–phenprocoumon	4	0.8	Average	3	M	Bleeding
Tramadol–quetiapine	4	0.8	Average	3	A / M	Sedation, seizures

[a] ORCA notation: 1 = contraindicated, 2 = provisionally contraindicated, 3 = conditional risk

[b] D, Desired interaction; A, consider an available alternative; M, special monitoring recommended

Table 7 Prescriptions without recommended dose adjustment for impaired renal function

Drug	Number of prescriptions without adjustment	GFR range (ml/min)	Recommended maximum dose (mg/day)	Actual dose range (mg/day)	Risk of related adverse event
Metformin	8	30–59	850	1,000–1,700	Major
Diclofenac	2	39–57	75	100–150	Major[a]
Metamizol	2	29–30	Avoid high doses	4,000	Major[a]
Perindopril	1	48	2	8	Major[a]
Rosuvastatin	1	25	Avoid	10	Major
Paracetamol	39	25–59	2,500	4,000	Minor
Atenolol	1	32	50	75	Minor
Hydrochlorothiazide	1	29	Avoid	12.5	Minor
Pregabalin	1	51	300	375	Minor

[a] The combination of NSAIDs, angiotensin-converting enzyme inhibitors, and preexisting renal impairment is an important risk factor for acute renal failure, particularly if doses are not adjusted

Conclusions

This study used a new method for the automated analysis of pharmacotherapy with a CDSS and was therefore able to identify drug interactions in prescription data of a selected patient population with high efficiency. The results of such retrospective analyses can be used for the development of targeted measures to improve medication safety directly where they have been identified in the past. Reclassification of the identified interactions according to a multidimensional operational interaction classification system suggests that only a minor fraction of all identified interactions involves a substantial risk. The implementation of such a classification into a refined CDSS may reduce over-alerting and consequently improve usability and therefore the efficacy of a CDSS to prevent adverse drug events in clinical practice. Future studies should investigate the impact of this approach on the prevention of adverse drug events in clinical practice.

References

1. Bates DW, Cullen DJ, Laird N, Petersen LA, Small SD, Servi D, Laffel G, Sweitzer BJ, Shea BF, Hallisey R et al (1995) Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group. JAMA 274(1):29–34
2. Classen DC, Pestotnik SL, Evans RS, Lloyd JF, Burke JP (1997) Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA 277(4):301–306
3. Lazarou J, Pomeranz BH, Corey PN (1998) Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 279(15):1200–1205
4. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, Farrar K, Park BK, Breckenridge AM (2004) Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. Br Med J 329(7456):15–19
5. Vonbach P, Dubied A, Beer JH, Krähenbühl S (2007) Recognition and management of potential drug–drug interactions in patients on internal medicine wards. Eur J Clin Pharmacol 63(11):1075–1083
6. Kaushal R, Shojania KG, Bates DW (2003) Effects of computerized physician order entry and clinical decision support systems on medication safety: a systematic review. Arch Intern Med 163 (12):1409–1416
7. Raschke RA, Gollihare B, Wunderlich TA, Guidry JR, Leibowitz AI, Peirce JC, Lemelson L, Heisler MA, Susong C (1998) A computer alert system to prevent injury from adverse drug events: development and evaluation in a community teaching hospital. JAMA 280(15):1317–1320
8. Bates DW, Teich JM, Lee J, Seger D, Kuperman GJ, Ma'Luf N, Boyle D, Leape L (1999) The impact of computerized physician order entry on medication error prevention. J Am Med Inform Assoc 6(4):313–321
9. Lin CP, Payne TH, Nichol WP, Hoey PJ, Anderson CL, Gennari JH (2008) Evaluating clinical decision support systems: monitoring CPOE order check override rates in the Department of Veterans Affairs' Computerized Patient Record System. J Am Med Inform Assoc 15(5):620–626
10. van der Sijs H, Aarts J, Vulto A, Berg M (2006) Overriding of drug safety alerts in computerized physician order entry. J Am Med Inform Assoc 13(2):138–147
11. Weingart SN, Toth M, Sands DZ, Aronson MD, Davis RB, Phillips RS (2003) Physicians' decisions to override computerized drug alerts in primary care. Arch Intern Med 163(21):2625–2631
12. Taylor LK, Tamblyn R (2004) Reasons for physician non-adherence to electronic drug alerts. Stud Health Technol Inform 107(Pt 2):1101–1105
13. Lin J, Knight EL, Hogan ML, Singh AK (2003) A comparison of prediction equations for estimating glomerular filtration rate in adults without kidney disease. J Am Soc Nephrol 14(10):2573–2580
14. Aronoff GR, Bennett WM, Berns JS (2007) Drug prescribing in renal failure: dosing guidelines for adults and children. American College of Physicians, Philadelphia
15. Hansten PD, Horn JR, Hazlet TK (2001) ORCA: OpeRational ClassificAtion of drug interactions. J Am Pharm Assoc (Wash) 41 (2):161–165
16. Hansten PD, Horn JR (2010) Drug interactions: analysis and management. Wolters Kluwer Health, St. Louis
17. Baxter K, Stockley IH (2010) Stockley's drug interactions : a source book of interactions, their mechanisms, clinical importance, and management. Pharmaceutical Press, London/Chicago
18. Malone DC, Abarca J, Hansten PD, Grizzle AJ, Armstrong EP, Van Bergen RC, Duncan-Edgar BS, Solomon SL, Lipton RB (2004) Identification of serious drug-drug interactions: results of the partnership to prevent drug-drug interactions. J Am Pharm Assoc 44(2):142–151
19. Hinz B, Cheremina O, Bachmakov J, Renner B, Zolk O, Fromm MF, Brune K (2007) Dipyrone elicits substantial inhibition of peripheral cyclooxygenases in humans: new insights into the pharmacology of an old analgesic. FASEB J 21(10):2343–2351
20. Graff J, Arabmotlagh M, Cheung R, Geisslinger G, Harder S (2007) Effects of parecoxib and dipyrone on platelet aggregation in patients undergoing meniscectomy: a double-blind, randomized, parallel-group study. Clin Ther 29(3):438–447